Advancements in Dry Powder Delivery to the Lung

REFERENCES

• D. Acerbi, G. Brambilla, and I. Kottakis. (2007). Advances in asthma and COPD management: Delivering CFC-free inhaled therapy using Modulite (R) technology. Pulm. Pharmacol. Ther. 20:290–303.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. (2003). Insulin administration. Diabetes Care 26:S121–S124.
   PubMedGoogle Scholar
• I. Ashurst, A. Malton, D. Prime, and B. Sumby. (2000). Latest advances in the development of dry powder inhalers. Pharm. Sci. Technol. Today 3:246–256.
   PubMedGoogle Scholar
• A. Ben-Jebria, M. L. Eskew, and D. A. Edwards. (2000). Inhalation system for pulmonary aerosol drug delivery in rodents using large porous particles. Aerosol Sci. Technol. 32:421–433.
   Web of Science ®Google Scholar
• S. Bindra, and W. T. Cedalu. (2002). Inhaled therapeutic systems. Curr. Opin. Investig. Drugs 3:758–762.
   PubMedGoogle Scholar
• L. Borgstrom, L. Asking, and P. Lipniunas. (2005). An in vivo and in vitro comparison of two powder inhalers following storage at hot/humid conditions. J. Aerosol Med. 18:304–310.
   PubMedGoogle Scholar
• L. Borgstrom, E. Bondesson, F. Moren, E. Trofast, and S. P. Newman. (1994). Lung deposition of budesonide inhaled via Tubuhaler®—A comparison with terbutaline sulphate in normal subjects. Eur. Respir. J. 7:69–73.
   PubMed Web of Science ®Google Scholar
• G. Brambilla, D. Ganderton, R. Garzia, D. Lewis, B. Meakin, and P. Ventura. (1999). Modulation of aerosol clouds produced by pressurised inhalation aerosols. Int. J. Pharm. 186:53–61.
   PubMed Web of Science ®Google Scholar
• M. A. Braun, R. Oschmann, and P. C. Schmidt. (1996). Influence of excipients and storage humidity on the deposition of disodium cromoglycate (DSCG) in the twin impinger. Int. J. Pharm. 135:53–62.
   Web of Science ®Google Scholar
• M. E. A. C. Breeders, J. Molema, N. A. Vermue, and H. Th. M. Folgering. (2001). Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers. Eur. Respir. J. 18:780–783.
   PubMed Web of Science ®Google Scholar
• B. A. S. Brwon, J. A. Rasmussen, D. P. Becker, and D. R. Friend. (2004). A piezo-electronic inhaler for local & systemic applications. Drug Deliv. Technol. 4:90–93.
   Google Scholar
• J. C. Cappelleri, W. T. Cefalu, J. Rosenstock, I. A. Kourides, and R. A. Gerber. (2002). Treatment satisfaction in type 2 diabetes: A comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin. Ther. 24:552–564.
   PubMed Web of Science ®Google Scholar
• U. H. Cegla. (2004). Pressure and inspiratory flow characteristics of dry powder inhalers. Respir. Med. 98:S22–S28.
   PubMed Web of Science ®Google Scholar
• H. Chrystyn. (2006). Closer to an “ideal inhaler” with the easyhaler (R)—an innovative dry powder inhaler. Clin. Drug Investig. 26:175–183.
   PubMed Web of Science ®Google Scholar
• M. G. Cochrane, M. V. Bala, K. E. Downs, J. Mauskopf, and R. H. Ben-Joseph. (2000). Inhaled corticosteroids for asthma therapy—patient compliance, devices, and inhalation technique. Chest 117:542–550.
   PubMed Web of Science ®Google Scholar
• R. O. Cook, R. K. Pannu, and I. W. Kellaway. (2005). Novel sustained release microspheres for pulmonary drug delivery. J. Control. Release 104:79–90.
   PubMed Web of Science ®Google Scholar
• D. O. Corrigan, A. M. Healy, and O. I. Corrigan. (2006). Preparation and release of salbutamol from chitosan and chitosan co-spray dried compacts and multiparticulates. Eur. J. Pharm. Biopharm. 62:295–305.
   PubMed Web of Science ®Google Scholar
• J. Cramer, J. Okikawa, and P. Clauson. (2003). Compliance with inhaled insulin treatment using AERx® iDMS insulin diabetes management system. Diabetes 52:A103–A103.
   Web of Science ®Google Scholar
• T. M. Crowder. (2004). Vibration technology for active dry-powder inhalers. Pharm. Technol. 28:52–59.
   Google Scholar
• R. Dalby, M. Spallek, and T. Voshaar. (2004). A review of the development of Respimat® soft Mist™ Inhaler. Int. J. Pharm. 283:1–9.
   PubMed Web of Science ®Google Scholar
• A. H. De Boer, D. Gjaltema, P. Hagedoorn, and H. W. Frijlink. (2004). Comparative in vitro performance evaluation of the Novopulmon®200 Novolizer® and Budesonid-ratiopharm® Jethaler: Two novel budesonide dry powder inhalers. Pharmazie 59:692–699.
   PubMed Web of Science ®Google Scholar
• A. H. De Boer, P. Hagedoorn, D. Gjaltema, J. Goede, and H. W. Frijlink. (2003). Air classifier technology (ACT) in dry powder inhalation—Part I. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures. Int. J. Pharm. 260:187–200.
   PubMed Web of Science ®Google Scholar
• A. H. De Boer, P. Hagedoorn, D. Gjaltema, J. Goede, and H. W. Frijlink. (2006a). Air classifier technology (ACT) in dry powder inhalation—Part 3. Design and development of an air classifier family for the Novolizer® multi-dose dry powder inhaler. Int. J. Pharm. 310:72–80.
   PubMed Web of Science ®Google Scholar
• A. H. De Boer, P. Hagedoorn, D. Gjaltema, J. Goede, and H. W. Frijlink. (2006b). Air classifier technology (ACT) in dry powder inhalation—Part 4. Performance of air classifier technology in the Novolizer® multi-dose dry powder inhaler. Int. J. Pharm. 310:81–89.
   PubMed Web of Science ®Google Scholar
• A. H. De Boer, H. M. I. Winter, and C. F. Lerk. (1996). Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers.1. Inhalation characteristics, work of breathing and volunteers’ preference in dependence of the inhaler resistance. Int. J. Pharm. 130:231–244.
   Web of Science ®Google Scholar
• L. A. Dellamary, T. E. Tarara, D. J. Smith, C. H. Woelk, A. Adractas, M. L. Costello, H. Gill, and J. G. Weers. (2000). Hollow porous particles in metered dose inhalers. Pharm. Res. 17:168–174.
   PubMed Web of Science ®Google Scholar
• M. DeLong, J. Wright, M. Dawson, T. Meyer, K. Sommerer, and C. Dunbar. (2005). Dose delivery characteristics of the AIR® pulmonary delivery system over a range of inspiratory flow rates. J. Aerosol Med. 18:452–459.
   PubMedGoogle Scholar
• M. Dolovich. (1999a). New delivery systems and propellants. Can. Respir. J. 6:290–295.
   PubMedGoogle Scholar
• M. Dolovich. (1999b). New propellant-free technologies under investigation. J. Aerosol Med. 12:S9–S17.
   Google Scholar
• S. P. Duddu, S. A. Sisk, Y. H. Walter, T. E. Tarara, K. R. Trimble, A. R. Clark, M. A. Eldon, R. C. Elton, M. Pickford, P. H. Hirst, S. P. Newman, and J. G. Weers. (2002). Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere® powder. Pharm. Res. 19:689–695.
   PubMed Web of Science ®Google Scholar
• C. A. Dunbar, A. J. Hickey, and P. Holzner. (1998). Dispersion and characterization of pharmaceutical dry powder aerosols. KONA 16:7–44.
   Google Scholar
• C. Dunbar, G. Scheuch, K. Sommerer, M. DeLong, A. Verma, and R. Batycky. (2002). In vitro and in vivo dose delivery characteristics of large porous particles for inhalation. Int. J. Pharm. 245:179–189.
   PubMed Web of Science ®Google Scholar
• D. A. Edwards, J. Hanes, G. Caponetti, J. Hrkach, A. BenJebria, M. L. Eskew, J. Mintzes, D. Deaver, N. Lotan, and R. Langer. (1997). Large porous particles for pulmonary drug delivery. Science 276:1868–1871.
   PubMed Web of Science ®Google Scholar
• S. L. Ellis, K. A. Gemperline, and S. K. Garg. (2007). Review of phase 2 studies utilizing the AIR® particle technology in the delivery of human insulin inhalation powder versus subcutaneous regular or lispro insulin in subjects with type 1 or type 2 diabetes. Diabetes Technol. Ther. 9:S48–S56.
   PubMed Web of Science ®Google Scholar
• C. Fenton, G. M. Keating, and G. L. Plosker. (2003). Novolizer®—a multidose dry powder inhaler. Drugs 63:2437–2445.
   PubMed Web of Science ®Google Scholar
• Guidance for Industry, Metered Dose Inhaler (MDI), and Dry Powder Inhaler (DPI) Drug Products. (1998).
   Google Scholar
• N. J. Harper, S. Gray, J. De Groot, J. M. Parker, N. Sadrzadeh, C. Schuler, J. D. Schumacher, S. Seshadri, A. E. Smith, G. S. Steeno, C. L. Stevenson, R. Taniere, M. Wang, and D. B. Bennett. (2007). The design and performance of the Exubera® pulmonary insulin delivery system. Diabetes Technol. Ther. 9:S16–S27.
   PubMed Web of Science ®Google Scholar
• L. Hendeles, G. L. Colice, and R. J. Meyer. (2007). Current concepts—withdrawal of albuterol inhalers containing chlorofluorocarbon propellants. N. Engl. J. Med. 356:1344–1351.
   PubMed Web of Science ®Google Scholar
• P. H. Hirst, S. P. Newman, D. A. Clark, and M. G. L. Hertog. (2002). Lung deposition of budesonide from the novel dry powder inhaler Airmax™. Respir. Med. 96:389–396.
   PubMed Web of Science ®Google Scholar
• D. Kohler. (2004). The Novolizer®: Overcoming inherent problems of dry powder inhalers. Respir. Med. 98:S17–S21.
   PubMed Web of Science ®Google Scholar
• G. Kunkel, C. Schaper, O. Noga, S. Schlafke, G. Lemmnitz, and S. Kohler. (2003). Efficacy, safety, and acceptance of beclomethasone dipropionate administered via a new dry powder inhaler or a standard CFC metered-dose inhaler in asthma patients. Respiration 70:399–406.
   PubMed Web of Science ®Google Scholar
• N. R. Labiris, and M. B. Dolovich. (2003a). Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56:588–599.
   PubMed Web of Science ®Google Scholar
• N. R. Labiris, and M. B. Dolovich. (2003b). Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56:600–612.
   PubMed Web of Science ®Google Scholar
• C. L. Leach, P. J. Davidson, and R. J. Boudreau. (1998). Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur. Respir. J. 12:1346–1353.
   PubMed Web of Science ®Google Scholar
• V. P. Lehto, and T. Lankinen. (2004). Moisture transfer into medicament chambers equipped with a double-barrier-desiccant system. Int. J. Pharm. 275:155–164.
   PubMed Web of Science ®Google Scholar
• D. Lewis. (2007). Metered-dose inhalers: Actuators old and new. Expert Opin. Drug Deliv. 4:235–245.
   PubMed Web of Science ®Google Scholar
• J. G. Lim, B. Shah, S. Rohatagi, and A. Bell. (2006). Development of a dry powder inhaler, the Ultrahaler, containing triamcinolone acetonide using in vitro-in vivo relationships. Am. J. Ther. 13:32–42.
   PubMedGoogle Scholar
• L. Maggi, R. Bruni, and U. Conte. (1999). Influence of the moisture on the performance of a new dry powder inhaler. Int. J. Pharm. 177:83–91.
   PubMed Web of Science ®Google Scholar
• T. K. Mandal. (2005). Inhaled insulin for diabetes mellitus. Am. J. Health Syst. Pharm. 62:1359–1364.
   PubMed Web of Science ®Google Scholar
• J. P. Mayer, F. Zhang, and R. D. DiMarchi. (2007). Insulin structure and function. Biopolymers 88:687–713.
   PubMed Web of Science ®Google Scholar
• K. J. McDonald, and G. P. Martin. (2000). Transition to CFC-free metered dose inhalers—into the new millennium. Int. J. Pharm. 201:89–107.
   PubMed Web of Science ®Google Scholar
• B. J. Meakin, J. Cainey, and P. M. Woodcock. (1993). Effect of exposure to humidity on turbutaline delivery from tubuhaler dry powder inhalation devices. Eur. Respir. J. 6:760–761.
   PubMed Web of Science ®Google Scholar
• R. Melchor, M. F. Biddiscombe, V. H. F. Mak, M. D. Short, and S. G. Spiro. (1993). Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible air-flow obstruction. Thorax 48:506–511.
   PubMed Web of Science ®Google Scholar
• M. J. Molina, and F. S. Rowland. (1974). Stratospheric risk for chlorofluoromethanes: Chlorine atom-catalysed destruction of ozone. Nature 249:810–812.
   Web of Science ®Google Scholar
• A. C. Moore, and S. Stone. (2004). Meeting the needs of patients with COPD: Patients’ preference for the Diskus inhaler compared with the Handihaler. Int. J. Clin. Pract. 58:444–450.
   PubMed Web of Science ®Google Scholar
• http://www.ondrugdelivery.com/publications/pulmonary.pdf Morton, D., & Staniforth, J. (2006). Systemic pulmonary delivery: Success through integrated formulation and device development..
   Google Scholar
• D. B. Muchmore, B. Silverman, A. de la Pena, and J. Tobian. (2007). The AIR® Inhaled Insulin System: System components and pharmacokinetic/glucodynamic data. Diabetes Technol. Ther. 9:S41–S47.
   PubMed Web of Science ®Google Scholar
• C. J. Musante, J. D. Schroeter, J. A. Rosati, T. M. Crowder, A. J. Hickey, and T. B. Martonen. (2002). Factors affecting the deposition of inhaled porous drug particles. J. Pharm. Sci. 91:1590–1600.
   PubMed Web of Science ®Google Scholar
• H. Nelson, J. P. Kemp, S. Bieler, L. M. Vaughan, and M. R. Hill. (1999). Comparative efficacy and safety of albuterol sulfate spiros inhaler and albuterol metered-dose inhaler in asthma. Chest 115:329–335.
   PubMed Web of Science ®Google Scholar
• M. T. Newhouse, P. H. Hirst, S. P. Duddu, Y. H. Walter, T. E. Tarara, A. R. Clark, and J. G. Weers. (2003). Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 124:360–366.
   PubMed Web of Science ®Google Scholar
• M. T. Newhouse, N. P. Nantel, C. B. Chambers, B. Pratt, and M. Parry-Billings. (1999). Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates. Chest 115:952–956.
   PubMed Web of Science ®Google Scholar
• S. P. Newman. (1990). Metered dose pressurized aerosols and the ozone layer. Eur. Respir. J. 3:495–497.
   PubMed Web of Science ®Google Scholar
• S. P. Newman, A. Hollingworth, and A. R. Clark. (1994). Effect of different modes of inhalation on drug-delivery from a dry powder inhaler. Int. J. Pharm. 102:127–132.
   Web of Science ®Google Scholar
• S. Newman, S. Malik, P. Hirst, G. Pitcairn, A. Heide, J. Pabst, A. Dinkelaker, and W. Fleischer. (2002). Lung deposition of salbutamol in healthy human subjects from the MAGhaler dry powder inhaler. Respir. Med. 96:1026–1032.
   PubMed Web of Science ®Google Scholar
• S. P. Newman, G. R. Pitcairn, P. H. Hirst, R. E. Bacon, E. O'Keefe, M. Reiners, and R. Hermann. (2000). Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur. Respir. J. 16:178–183.
   PubMed Web of Science ®Google Scholar
• B. J. O'Connor. (2004). The ideal inhaler: Design and characteristics to improve outcomes. Respir. Med. 98:S10–S16.
   PubMed Web of Science ®Google Scholar
• R. J. Oenbrink. (1993). Unexpected adverse effects of Freon 11 and Freon 12 as medication propellants. J. Am. Osteopath. Assoc. 93:714–718.
   PubMedGoogle Scholar
• M. Parry-Billings, R. N. Boyes, L. M. Clisby, P. Braithwaite, S. Williams, and A. E. Harper. (1999). Design, development and performance of a novel multidose dry-powder inhaler. Med. Device Technol. 10:32–34.
   Google Scholar
• J. S. Patton. (1996). Mechanisms of macromolecule absorption by the lungs. Adv. Drug Deliv. Rev. 19:3–36.
   Web of Science ®Google Scholar
• J. S. Patton. (1997). Deep-lung delivery of therapeutic proteins. Chemtech 27:34–38.
   Google Scholar
• J. S. Patton. (2005). Unlocking the opportunity of tight glycaemic control. Innovative delivery of insulin via the lung. Diabetes, Obes. Metab. 7:S5–S8.
   PubMedGoogle Scholar
• J. S. Patton, J. Bukar, and S. Nagarajan. (1999). Inhaled insulin. Adv. Drug Deliv. Rev. 35:235–247.
   PubMed Web of Science ®Google Scholar
• J. Peart, and M. J. Clarke. (2001). New developments in dry powder inhaler technology. Am. Pharm. Rev. 4:37–45.
   Google Scholar
• J. Peart, C. Magyer, and P. R. Byron. Aerosol electrostatics—metered dose inhalers (MDIs): Reformulation and device design issuesProceedings of Respiratory Drug Delivery VISouth Carolina, (1998), 227–233.
   Google Scholar
• G. R. Pitcairn, T. Lankinen, O. P. Seppala, and S. P. Newman. (2000). Pulmonary drug delivery from the taifun dry powder inhaler is relatively independent of the patient's inspiratory effort. J. Aerosol Med. 13:97–104.
   PubMedGoogle Scholar
• G. R. Pitcairn, J. Lim, A. Hollingworth, and S. P. Newman. (1997). Scintigraphic assessment of drug delivery from the ultrahaler dry powder inhaler. J. Aerosol Med. 10:295–306.
   PubMedGoogle Scholar
• G. Pitcairn, G. Lunghetti, P. Ventura, and S. Newman. (1994). A comparison of the lung deposition of salbutamol inhaled from a new dry powder inhaler. Int. J. Pharm. 102:11–18.
   Web of Science ®Google Scholar
• K. Rave, L. Nosek, L. Heinemann, C. Gonzales, C. S. Ernest, J. Chien, and D. Muchmore. (2004). Inhaled micronized crystalline human insulin using a dry powder inhaler: Dose-response and time-action profiles. Diabet. Med. 21:763–768.
   PubMed Web of Science ®Google Scholar
• P. C. Richardson, and A. H. Boss. (2007). Technosphere® Insulin technology. Diabetes Technol. Ther. 9:S65–S72.
   PubMed Web of Science ®Google Scholar
• K. Richter. (2004). Successful use of DPI systems in asthmatic patients—key parameters. Respir. Med. 98:S22–S27.
   PubMed Web of Science ®Google Scholar
• G. Saint-Lorant, P. Leterme, A. Gayot, and M. P. Flament. (2007). Influence of carrier on the performance of dry powder inhalers. Int. J. Pharm. 334:85–91.
   PubMed Web of Science ®Google Scholar
• P. S. A. Sarinas, T. E. Robinson, A. R. Clark, J. Canfield, R. K. Chitkara, and R. B. Fick. (1998). Inspiratory flow rate and dynamic lung function in cystic fibrosis and chronic obstructive lung diseases. Chest 114:988–992.
   PubMed Web of Science ®Google Scholar
• T. Sebti, G. Pilcer, B. Van Gansbeke, S. Goldman, A. Michils, F. Vanderbist, and K. Amighi. (2006). Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation. Eur. J. Pharm. Biopharm. 64:26–32.
   PubMed Web of Science ®Google Scholar
• S. A. Shoyele, and A. Slowey. (2006). Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery. Int. J. Pharm. 314:1–8.
   PubMed Web of Science ®Google Scholar
• I. J. Smith, and M. Parry-Billings. (2003). The inhalers of the future? A review of dry powder devices on the market today. Pulm. Pharmacol. Ther. 16:79–95.
   PubMed Web of Science ®Google Scholar
• H. D. C. Smyth, and A. J. Hickey. (2005). Carriers in drug powder delivery: Implications for inhalation system design. Am. J. Drug Deliv. 3:117–132.
   Google Scholar
• D. Stanescu, C. Veriter, and K. P. Van de Woestijne. (2000). Maximal inspiratory flow rates in patients with COPD. Chest 118:976–980.
   PubMed Web of Science ®Google Scholar
• H. Steckel, and B. W. Muller. (1997). In vitro evaluation of dry powder inhalers.1. Drug deposition of commonly used devices. Int. J. Pharm. 154:19–29.
   Web of Science ®Google Scholar
• H. Steckel, P. Markefka, H. TeWierik, and R. Kammelar. (2004). Functionality testing of inhalation grade lactose. Eur. J. Pharm. Biopharm. 57:495–505.
   PubMed Web of Science ®Google Scholar
• W. Y. Tarsin, S. B. Pearson, K. H. Assi, and H. Chrystyn. (2006). Emitted dose estimates from Seretide® Diskus® and Symbicort® Turbuhaler® following inhalation by severe asthmatics. Int. J. Pharm. 316:131–137.
   PubMedGoogle Scholar
• R. Thibert, M. Parry-Billings, and M. Shott. (2002). Clickhaler® dry powder inhaler: Focussed in vitro proof of principle evaluation of a new chemical entity for asthma. Int. J. Pharm. 239:149–156.
   PubMedGoogle Scholar
• H. A. Tiddens, D. E. Geller, P. Challoner, R. J. Speirs, K. C. Kesser, S. E. Overbeek, D. Humble, S. B. Shrewsbury, and T. A. Standaert. (2006). Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J. Aerosol Med. 19:456–465.
   PubMedGoogle Scholar
• M. Tobyn, J. N. Staniforth, D. Morton, Q. Harmer, and M. E. Newton. (2004). Active and intelligent inhaler device development. Int. J. Pharm. 277:31–37.
   PubMedGoogle Scholar
• A. Valente, R. Langer, H. A. Stone, and D. A. Edwards. (2003). Recent advances in the development of an inhaled insulin product. BioDrugs 17:9–17.
   PubMed Web of Science ®Google Scholar
• R. Vanbever, J. D. Mintzes, J. Wang, J. Nice, D. H. Chen, R. Batycky, R. Langer, and D. A. Edwards. (1999). Formulation and physical characterization of large porous particles for inhalation. Pharm. Res. 16:1735–1742.
   PubMed Web of Science ®Google Scholar
• S. K. Vaswani, and P. S. Creticos. (1998). Metered dose inhaler: Past, present, and future. Ann. Allergy Asthma Immunol. 80:11–19.
   PubMed Web of Science ®Google Scholar
• M. Vidgren, J. Arppe, P. Vidgren, L. Hyvarinen, P. Vainio, M. Silvasti, and H. Tukiainen. (1994). Pulmonary deposition and clinical response of TC-99m-labeled salbutamol delivered from a novel multiple-dose powder inhaler. Pharm. Res. 11:1320–1324.
   PubMed Web of Science ®Google Scholar
• M. K. A. Vidgren, A. Karkkainen, P. Karjalainen, J. Nuutinen, and P. Paronen. (1988). Effect of powder inhaler design on drug deposition in the respiratory tract. Int. J. Pharm. 42:211–216.
   Web of Science ®Google Scholar
• M. Vidgren, M. Silvasti, P. Vidgren, H. Sormunen, K. Laurikainen, and P. Korhonen. (1995). Easyhaler® multiple-dose powder inhaler-practical and effective alternative to the pressurized MDI. Aerosol Sci. Technol. 22:335–345.
   Web of Science ®Google Scholar
• A. Voss, and W. H. Finlay. (2002). Deagglomeration of dry powder pharmaceutical aerosols. Int. J. Pharm. 248:39–50.
   PubMed Web of Science ®Google Scholar
• S. Warren, and G. Taylor. (1998). Effect of inhalation flow profiles on the deposition of radiolabelled BDP from a novel dry powder inhaler (DPI, clickhaler), a conventional metered dose inhaler(MDI), and MDI plus spacer. Respir. Drug Deliv. VI:453–455.
   Google Scholar
• S. Warren, G. Taylor, C. Godfrey, G. Cote, and M. Hill. (1999). Gamma scintigraphic evaluation of dry powder beclomethasone dipropionate (BDP) from an investigational spiros® inhaler: Effect of inspiratory flow profile on pulmonary drug deposition. Am. J. Respir. Crit. Care Med. 159:A118–A118.
   Web of Science ®Google Scholar
• P. M. Young, R. Price, M. J. Tobyn, M. Buttrum, and F. Dey. (2003). Investigation into the effect of humidity on drug-drug interactions using the atomic force microscope. J. Pharm. Sci. 92:815–822.
   PubMed Web of Science ®Google Scholar
• M. Zeidler, and J. Corren. (2004). Hydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthma. Treat. Respir. Med. 3:35–44.
   PubMedGoogle Scholar
• X. M. Zeng, S. Jones, D. O'Leary, M. Phelan, and J. Colledge. (2002a). Delivery of formoterol from a novel multi-dose inhaler Airmax™. Respir. Med. 96:397–403.
   PubMed Web of Science ®Google Scholar
• X. M. Zeng, G. Martin, and C. Marriot. Particulate interactions in dry powder formulations for inhalation Taylor and Francis, New York, (2001).
   Google Scholar
• X. M. Zeng, D. O'Leary, M. Phelan, S. Jones, and J. Colledge. (2002b). Delivery of salbutamol and of budesonide from a novel multi-dose inhaler Airmax™. Respir. Med. 96:404–411.
   PubMed Web of Science ®Google Scholar